Autolus Upgrades Leadership And Faces CAR-T Approval

Fly View Productions My initial coverage of Autolus Therapeutics (NASDAQ:AUTL), now a $1 billion market cap clinical-stage biopharmaceutical company, rated it a Strong Buy for numerous positive catalysts for 2023. Investors who heeded this tip were rewarded, as the stock has skyrocketed nearly 150% to a 52-week high of $7.45 since publication. Shares have dipped about 20% after the FDA required black box warnings (“BBW”) for certain cell therapies to reflect a risk of T-cell malignancies. Most of Autolu ...